Cochrane Evidence Synthesis and Methods ►

Immune checkpoint inhibitors (anti PD-1 or anti PD-L1) plus platinum-etoposide versus platinum-etoposide alone for first-line treatment of extensive small cell lung cancer

This is a protocol for a Cochrane Review (intervention). The objectives are as follows:

To evaluate the efficacy and safety of immune checkpoint inhibitors (anti PD-1 or anti PD-L1) plus platinum-etoposide compared with platinum-etoposide alone for the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC).

This is a protocol.

Published:

19 October 2021

Authors:

Gao Y, Shi S, Liu M, Wu F, Zhang J, Song F, Tian J

See the full Review on

the Cochrane Library

►

Was this helpful? Donate.

If you found this evidence helpful, please consider donating to Cochrane. We are a charity that produces accessible evidence to help people make health and care decisions.
Donate
Print
PDF
Citation
Gao Y, Shi S, Liu M, Wu F, Zhang J, Song F, Tian J. Immune checkpoint inhibitors (anti PD-1 or anti PD-L1) plus platinum-etoposide versus platinum-etoposide alone for first-line treatment of extensive small cell lung cancer (Protocol). Cochrane Database of Systematic Reviews 2021, Issue 10. Art. No.: CD014809. DOI: 10.1002/14651858.CD014809.